




## How do I get more information?

To find out more, please contact the study team using the information provided here. Study participation is voluntary. By contacting us, you are under no obligation to take part in the study.



## Who can take part?

You may be able to take part in the LAURIET Study if you:

- are 50 to 85 years of age
- have moderate Alzheimer's disease (for example, confusion about dates and locations, difficulty recalling important events, and needing help with dressing)
- have somebody who can be a reliable study partner or caregiver and who can come to some study visits with you and answer questions about your health.



## Information for patients

To the caregiver/study partner: In this Brochure, “you” and “your” refers to the person with Alzheimer's disease. However, we hope that you will also find this information useful.

**Genentech**  
A Member of the Roche Group

**Lauriet**  
GN40040

## About Alzheimer's disease

- Alzheimer's disease is the most common cause of dementia among older adults. Dementia is the loss of brain function, causing problems with memory. Dementia may cause a decline in thinking abilities to such an extent that it interferes with a person's daily life and activities.
- There is no cure for Alzheimer's disease. There is currently no treatment to stop or reverse the memory loss and decline in thinking abilities caused by this disease. Scientists and medical researchers are searching for new treatment options to better support people with Alzheimer's disease in the future.




## About the LAURIET Study

The LAURIET Study will test how safe the investigational medication is and whether it works in affecting Alzheimer's disease. The study will also use imaging (using a scanner to make a detailed picture) to look at how the investigational medication affects certain substances in the brain.

Some patients in the study will receive a placebo (which looks the same as the investigational medication but contains no actual medication). Other people will receive the investigational medication. This way the researchers can see if there is any difference in effect between people receiving the investigational medication and people receiving placebo. You will have a 50% chance (1 in 2) of receiving the investigational medication and a 50% chance of receiving placebo.

## Taking part in the LAURIET Study

The study will start with a screening period and a baseline period, to check if the study is right for you and to have initial tests and procedures. In the treatment period that follows (only if you qualify for the study), you will not know whether you are getting the investigational medication or placebo. After the treatment period, you may be able to continue in an optional extension period, during which all participants will receive the investigational medication.



Your participation in the study will last up to approximately 38 months (a little over 3 years), if you take part in all the study periods.